Chronic Lower Back Pain (CLBP) Market Forecasts by DelveInsight Signal Groundbreaking Growth by 2032 | Eli Lilly, Camurus, Braeburn, Scilex, AnGesMG, Eliem Therapeutics, Allodynic, Sollis, DiscGenics, Pfizer, Vertanical, Stayble, SpineThera

The Chronic Lower Back Pain market is experiencing notable evolution, with a focus on multidisciplinary approaches to pain management and novel treatment modalities. Advancements in minimally invasive procedures, regenerative medicine, and digital health solutions are expanding therapeutic options for patients with Chronic Lower Back Pain.

DelveInsight's "Chronic Lower Back Pain Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Chronic Lower Back Pain Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The market report covers emerging drugs, treatment practices, market share of individual Chronic Lower Back Pain therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Chronic Lower Back Pain treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Chronic Lower Back Pain: An Overview
Chronic low back pain (CLBP) is pain that persists for 12 weeks or longer, even after an initial injury or underlying cause of acute low back pain. Low back pain is very common, and at one point, everyone must have faced this problem. Lower back pain that is long-term (for more than 3 months) is called CLBP. This condition might originate from an injury, disease, or stress on different body structures. The pain may vary significantly and be felt as bone pain, nerve pain, or muscle pain, and its intensity ranges from mild to severe.

The exact cause of this complex condition remains unclear. Due to its dynamic and fluctuating nature, its etiology and pathophysiology are more complex. While many patients with acute lower back pain improve clinically without specific treatment, it is less clear why others progress to develop recurrent or chronic symptoms. CLBP has adverse physical and psychological repercussions. It creates a significant economic burden due to loss of function, loss of work productivity, treatment costs, and disability payments.

CLBP is usually investigated by physician evaluation or by imaging studies. The primary goal of diagnosis is to characterize the pain as mechanical, primarily when history is obtained from a patient with CLBP and sciatica. The current treatment for CLBP involves both pharmacological and non-pharmacological treatment options.

Chronic Lower Back Pain Market Key Facts
• The Chronic Lower Back Pain market size in the 7MM is expected to rise from USD 6,227 million in 2020 at a CAGR of 3.85% for the study period (2019-2032).
• The United States accounted for the highest market size of Chronic Lower Back Pain, in comparison to the other major markets i.e., EU5 countries (the United Kingdom, Germany, Italy, France, and Spain), and Japan in 2020.
• Among the EU5 countries, Spain had the highest Chronic Lower Back Pain market size with USD 317 million in 2020, while Italy had the lowest market size of Chronic Lower Back Pain with USD 94 million in 2020.
• In 2020, the total prevalent population of Chronic Lower Back Pain was found out to be 76,440,725 in the 7MM, these cases are expected to grow at a CAGR of 0.55% for the study period 2019-2020.
• The estimates suggest the highest diagnosed prevalent cases of Chronic Lower Back Pain in the United States with 35,059,702 cases in 2020.
• The total number of Chronic Lower Back Pain cases in females was 17,291,445 and in males, it was 14,262,287 cases in 2020, in the US.
• The highest number of Chronic Lower Back Pain cases were in the age group 70+ years with 6,736,354 cases in the EU-5 and the least number of cases of Chronic Lower Back Pain were found in 18-29 years age group with 2,363,980 cases in 2020, in EU-5.
• Japan had 10,826,931 diagnosed prevalent cases of Chronic Lower Back Pain in 2020.

Get a Detailed Overview of the Evolving Chronic Lower Back Pain Market Trends @
https://www.delveinsight.com/report-store/chronic-lower-back-pain-clbp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Chronic Lower Back Pain Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Chronic Lower Back Pain therapies in the market. It also provides a detailed assessment of the Chronic Lower Back Pain market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete details of the market trend for each marketed Chronic Lower Back Pain drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Discover How the Chronic Lower Back Pain Market Will Grow by 2032 @
https://www.delveinsight.com/report-store/chronic-lower-back-pain-clbp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Chronic Lower Back Pain Epidemiology
The epidemiology section covers detailed insights into the historical, and current Chronic Lower Back Pain patient pool and forecasted epidemiology trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Chronic Lower Back Pain Epidemiology Segmented as -
• Total Prevalent Cases of CLBP in the 7MM [2019-2032]
• Total Diagnosed Prevalent Cases of CLBP in the 7MM [2019-2032]
• Gender- Specific Diagnosed Prevalent Cases of CLBP in the 7MM [2019-2032]
• Age-Specific Diagnosed Prevalent Cases of CLBP in the 7MM [2019-2032]

Get Key Insights Into the Evolving Chronic Lower Back Pain Epidemiology Trends @
https://www.delveinsight.com/report-store/chronic-lower-back-pain-clbp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Chronic Lower Back Pain Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Lower Back Pain market or expected to be launched during the study period. The analysis covers the market share by Chronic Lower Back Pain drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.

The report also covers the Chronic Lower Back Pain Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities in the Chronic Lower Back Pain Market @
https://www.delveinsight.com/sample-request/chronic-lower-back-pain-clbp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Chronic Lower Back Pain Therapeutics Assessment
A wide variety of pharmacological treatments are used to treat Chronic Lower Back Pain (CLBP); acetaminophen, non-steroidal anti-inflammatory drugs (NSAIDs), opioids, and anti-depressants are recommended for use, although it is not clear that anyone drug has an advantage and side effects complicate their use in the long-term.

Multiple trials are evaluating a plethora of medication classes for LBP, but aside from studies conducted in patients with radiculopathy, most have been performed in patients with axial LBP. There is strong evidence in support of non-steroidal anti-inflammatory drugs for chronic LBP compared with placebo for up to three months, but long-term outcome studies are lacking.

The therapeutic landscape of CLBP in Japan is similar to that of the United States, EU4, and the UK, with no drug approved, specifically for the management of CLBP in patients. Many people experience one or more episodes of LBP in their life and, as such, LBP is associated with high healthcare costs, work absenteeism, and disablement.

Several major pharma and biotech companies are actively involved in developing therapies for Chronic Lower Back Pain. Among these, certain companies have progressed their Chronic Lower Back Pain drug candidates to the most advanced stage of clinical development, specifically Phase III trials. Notably, Mesoblast stands out for its dedication to advancing innovative treatments for this prevalent and debilitating condition. These companies collectively represent a robust landscape of research and development endeavors aimed at addressing the complex challenges associated with Chronic Lower Back Pain and enhancing the well-being of affected individuals.

Leading Companies in the Chronic Lower Back Pain Therapeutics Market Include
Some of the prominent players in the Chronic Lower Back Pain Therapeutics Market include Eli Lilly and Company, Collegium Pharmaceuticals, Purdue Pharma LP, BioDelivery Sciences International, Camurus, Braeburn Inc., Scilex Holding, Mesoblast Limited, AnGesMG, Inc., Kolon Life Science, Eliem Therapeutics, Allodynic Therapeutics, Sollis Therapeutics, Medtronic Spinal and Biologics, Frontier Biotechnologies, DiscGenics Inc., Pfizer, Persica Pharmaceuticals, BioRestorative Therapies, Vertanical GmbH, Stayble Therapeutics, SpineThera, CHABiotech, Xgene Pharmaceuticals, Imbrium Therapeutics, and others.

Emerging and Marketed Chronic Lower Back Pain Therapies Covered in the Report Include
• Semdexa (SP-102): Scilex Holding
• MPC-06-ID: Mesoblast
• PP353: Persica Pharmaceuticals
• Brixadi/Buvidal (CAM2038/Buprenorphine Injection Depot): Camurus/Braeburn Inc.
And Many Others

Learn More About the Emerging Therapies and key Companies in the Chronic Lower Back Pain Therapeutics Market @
https://www.delveinsight.com/sample-request/chronic-lower-back-pain-clbp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Chronic Lower Back Pain Competitive Intelligence Analysis
4. Chronic Lower Back Pain Market Overview at a Glance
5. Chronic Lower Back Pain Background and Overview
6. Chronic Lower Back Pain Patient Journey
7. Chronic Lower Back Pain Epidemiology and Patient Population
8. Chronic Lower Back Pain Treatment Algorithm, Current Treatment, and Medical Practices
9. Chronic Lower Back Pain Unmet Needs
10. Key Endpoints of Chronic Lower Back Pain Treatment
11. Chronic Lower Back Pain Marketed Products
12. Chronic Lower Back Pain Emerging Therapies
13. Chronic Lower Back Pain Seven Major Market Analysis
14. Attribute Analysis
15. Chronic Lower Back Pain Market Outlook (7 major markets)
16. Chronic Lower Back Pain Access and Reimbursement Overview
17. KOL Views on the Chronic Lower Back Pain Market.
18. Chronic Lower Back Pain Market Drivers
19. Chronic Lower Back Pain Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings @
https://www.delveinsight.com/sample-request/chronic-lower-back-pain-clbp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.